MoleculeDx Journal · Patient education

Early Cancer Screening: How Fusion-detect™ Could Transform Liver Cancer Surveillance

Discover how molecular fusion-transcript testing could overcome limitations of conventional liver cancer surveillance and support a new approach to early detection.

Early detection is one of the most important goals of preventive cancer care. Many cancers develop gradually and may produce no noticeable symptoms during their early stages. Identifying cancer before symptoms appear can provide opportunities for earlier treatment and potentially better outcomes.

Cancer screening has traditionally relied on imaging, examination, and blood- or tissue-based biomarkers. Although these approaches have improved cancer care, their ability to detect early disease varies significantly between cancer types.

Advances in molecular diagnostics are introducing another possibility: identifying cancer-associated genetic signals in blood before a tumor becomes clinically apparent.

MoleculeDx is developing Fusion-detect™, a proprietary blood-based approach that uses circulating fusion-transcript signals to support the early detection of hepatocellular carcinoma (HCC), the most common primary liver cancer.

Why is early cancer screening important?

Cancer screening aims to identify possible malignancies in individuals who have not yet developed symptoms.

Several screening methods are well established. Mammography is used for breast cancer screening, colonoscopy and stool-based testing for colorectal cancer, and low-dose CT for lung cancer screening in eligible high-risk individuals.

These methods demonstrate the benefits of detecting cancer at an earlier, potentially more treatable stage. However, no single screening approach works equally well for every cancer.

Screening is also different from diagnosis. A positive screening result identifies a possible abnormality that requires further evaluation. Additional imaging, pathological examination, or other diagnostic procedures may be needed to confirm cancer.

The challenge of detecting liver cancer early

Hepatocellular carcinoma frequently develops in people with chronic liver disease, particularly cirrhosis and certain forms of chronic hepatitis B infection.

Patients may have substantial liver cancer risk without experiencing symptoms. Consequently, regular surveillance is recommended for selected high-risk individuals.

Traditional HCC surveillance commonly uses abdominal ultrasound combined with a blood test for alpha-fetoprotein (AFP), generally at six-month intervals.

However, these approaches have important limitations.

According to the 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance, a meta-analysis estimated that ultrasound alone had approximately 53% sensitivity for early-stage HCC, increasing to approximately 63% when ultrasound was combined with AFP. [1]

Ultrasound sensitivity can also be affected by cirrhosis, obesity, fatty liver changes, and the difficulty of visualizing small lesions.

AFP is not consistently elevated in patients with early HCC and can also increase in certain nonmalignant liver conditions.

These limitations underscore the need for more effective surveillance methods capable of identifying cancer-associated signals that traditional imaging and protein biomarkers may miss.

Molecular screening: A different approach to early cancer detection

Cancer development frequently involves changes in the genome and in the expression of cancer-associated genes.

Some genomic rearrangements join portions of different genes, generating abnormal RNA molecules known as fusion transcripts.

These transcripts can enter the bloodstream and may be detected in serum as circulating cell-free RNA.

Unlike ultrasound, which identifies structural changes in the liver, fusion-transcript testing evaluates molecular signals associated with cancer.

A study published in Oncotarget in 2019 demonstrated that selected fusion transcripts could be detected in serum samples from patients with HCC. [2]

Subsequent research published in the American Journal of Pathology in 2024 evaluated combinations of serum fusion transcripts using machine-learning approaches to assess HCC risk. [3]

These findings support the scientific potential of circulating fusion transcripts as blood-based biomarkers for liver cancer detection.

Fusion-detect™: Advancing molecular liver cancer surveillance

MoleculeDx developed Fusion-detect™ as a proprietary multivariable approach for detecting cancer-associated fusion-transcript signals in blood.

The company's Liver Cancer Fusion Predictor uses molecular information to identify patterns associated with HCC.

In clinical validation reported by MoleculeDx, Fusion-detect™ demonstrated:

  • 96.7% overall accuracy
  • 94.2% sensitivity
  • 98.1% specificity

These company-reported internal validation results demonstrate the potential of the technology within the evaluated clinical population.

They should not be interpreted as a direct head-to-head demonstration of superiority over ultrasound-plus-AFP surveillance or as a guarantee of performance in every patient population.

The key distinction is that Fusion-detect™ evaluates molecular cancer-associated signals rather than relying primarily on tumor visualization or AFP concentrations.

This approach offers the possibility of detecting HCC-associated abnormalities that may not be readily identified using traditional surveillance methods.

Could fusion-transcript testing replace conventional liver cancer surveillance?

MoleculeDx is pursuing a proposed clinical strategy in which the Liver Cancer Fusion Predictor could provide a molecular alternative to traditional ultrasound-plus-AFP surveillance for patients at increased risk of HCC.

Potential applications include using Fusion-detect™ as a stand-alone molecular surveillance approach or combining its results with ultrasound to provide complementary molecular and imaging information.

Such applications represent a possible shift from predominantly imaging- and protein-based surveillance toward molecular analysis of cancer-associated RNA.

The proposed replacement indication remains subject to FDA review and authorization. It should not be interpreted as an already authorized replacement for guideline-recommended HCC surveillance.

An abnormal molecular result requires appropriate clinical assessment and does not independently establish a definitive diagnosis of cancer.

The future of preventive cancer care

The evolution of cancer screening increasingly involves molecular technologies capable of detecting biological changes associated with malignancy.

For HCC, circulating fusion-transcript analysis represents a scientifically distinct opportunity to improve the identification of cancer-associated signals in blood.

The longer-term objective of Fusion-detect™ is to advance liver cancer surveillance beyond the limitations of conventional ultrasound and AFP testing.

By integrating molecular diagnostics into preventive cancer care, MoleculeDx aims to support earlier identification of liver cancer and expand the possibilities for improved surveillance strategies.

Early cancer detection is not simply about testing more frequently. It is also about developing better methods to identify cancer when effective intervention may still be possible.

Medical information disclaimer: This article provides general educational information and does not replace individualized medical advice, diagnosis, or treatment. Patients should discuss appropriate surveillance and diagnostic testing with qualified healthcare professionals.

References

1. Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–1965. doi:10.1097/HEP.0000000000000466.

2. Yu YP, Tsung A, Liu S, et al. Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma. Oncotarget. 2019;10:3352–3360. doi:10.18632/oncotarget.26918.

3. Yu YP, Liu S, Geller DA, Luo JH. Serum fusion transcripts to assess the risk of hepatocellular carcinoma and the impact of cancer treatment through machine learning. American Journal of Pathology. 2024;194:1262–1271. doi:10.1016/j.ajpath.2024.02.017.

← Back to the Journal

Educational information only; consult a qualified healthcare professional. Screening does not establish or exclude a diagnosis.